Comparison of two dosing schedules of flurbiprofen for patients with rheumatoid arthritis. Twice-daily versus four-times-a-day schedules.
A total daily dose of 200 mg of flurbiprofen (Ansaid, Upjohn) was administered either twice daily (100 mg BID) or four times daily (50 mg QID) to 143 patients with rheumatoid arthritis. Results of this 12-week, randomized, double-blind study showed statistically significant reductions in the number of swollen joints, number of affected joints, duration of morning stiffness, and 50-foot walk time in patients receiving either treatment regimen. Using standard statistical tests, no significant differences between regimens were found. Flurbiprofen treatment was rated as "excellent" or "good" by approximately half of the patients and physicians following both BID or QID dosing.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D005480:Flurbiprofen / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000008:administration & dosage*
D011422:Propionates; D005480:Flurbiprofen